Thermo Fisher Scientific, the world leader in serving science, has launched the Applied Biosystems™ SwiftArrayStudio™ Microarray Analyzer, a next-generation platform engineered for fast, scalable, and integrated sample analysis. Designed to streamline genomic workflows, the system integrates four key genotyping processes into a single device, enabling researchers to efficiently conduct large-scale Genome-Wide Association Studies (GWAS) and drive advances in pharmacogenomics to support the future of precision medicine.
The new analyzer is introduced alongside two innovative arrays — the Applied Biosystems Axiom™ PharmacoPro™ Array and the Applied Biosystems Axiom PangenomePro Array — together providing the broadest population coverage for genetic studies.
As genomic science continues to evolve, researchers require faster and simpler analytical workflows. Traditional methods often take days and demand significant hands-on time, while large laboratories face diverse customer requirements that can necessitate multiple instruments and specialized expertise.
Highlighting the system’s scientific advantage, Ulrich Broeckel, MD, founder and chief executive officer of RPRD Diagnostics, said:
“The SwiftArrayStudio genotyping platform offers unique advantages, especially for comprehensive pharmacogenetics genotyping, major relevant pharmacogenetics genes with CPIC guidelines, plus many ADME genes for research applications with deep coverage of both common as well as rare variants, allowing for the identification of both rare and less frequent haplotypes. Combined with the ability to process medium to high sample throughput, this offers versatility that is advantageous for pharmacogenetics.”
The SwiftArrayStudio Microarray Analyzer empowers laboratories to be more agile — scaling throughput seamlessly and optimizing performance as demand evolves, all while maintaining data quality. The all-in-one platform delivers results in as little as 30 hours* and can reduce hands-on time by up to 40 percent*. This improvement not only boosts efficiency but also lowers operational costs and complexity, enabling researchers to produce high-quality data faster and with less effort.
“For decades, our innovations in genetic research and genomics have shaped the way scientists explore biology and delivered new capabilities to applied markets,” said Rosy Lee, president, genetic sciences, Thermo Fisher Scientific.
“With this next-generation microarray platform, we are once again redefining what’s possible – leading the charge toward multi-omics and empowering researchers with a more complete view of biology that will accelerate discoveries in health and disease.”
The SwiftArrayStudio Analyzer pushes the boundaries of microarray technology, combining enhanced flexibility and robust performance to unlock population-scale genotyping and pharmacogenomics research, with the ultimate goal of bringing targeted treatments to patients faster.
“The SwiftArrayStudio analyzer represents more than just technical advancement – it’s an advancement for genomics research, powering a new generation of innovation for our customers,” said Ravi Gupta, vice president and general manager of Thermo Fisher Scientific’s microarray business.
“Designed as a single, expandable platform to meet future technological needs around genotyping, methylation, epigenetics, reproductive health, agrigenomics and many other applications, the platform delivers robust capabilities through an uncompromised user experience.”
The SwiftArrayStudio Microarray Analyzer will be showcased at Thermo Fisher’s booth (#736) during the American Society of Human Genetics (ASHG) Annual Meeting in Boston, Massachusetts, from October 14–18.
Also Read